The antitumor effect of oncolytic respiratory syncytial virus via the tumor necrosis factor-alpha induction and ROS-bax-mediated mechanisms.
Apoptosis
Autophagy
Human papillomavirus
Human respiratory syncytial virus
Oncolytic viruses
Reactive oxygen species
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
28 Aug 2023
28 Aug 2023
Historique:
received:
18
06
2023
accepted:
22
08
2023
medline:
31
8
2023
pubmed:
29
8
2023
entrez:
28
8
2023
Statut:
epublish
Résumé
Cervical cancer represents one of the most prevalent cancers among women worldwide, particularly in low- and middle-income nations. Oncolytic viruses (OVs) can infect cancer cells selectively and lethally without harming normal cells. Respiratory syncytial virus (RSV) is an oncolytic virus for anticancer therapy because of its propensity to multiply within tumor cells. This research aimed to assess the in vitro antitumor activities and molecular basis processes of the oncolytic RSV-A2 on the TC-1 cancer cells as a model for HPV‑related cervical cancers. Cellular proliferation (MTT) and lactate dehydrogenase (LDH) release assays were used to investigate the catalytic impacts of RSV-A2 by the ELISA method. Real-time PCR and flow cytometry assays were utilized to assess apoptosis, autophagy, intracellular concentrations of reactive oxygen species (ROS), and cell cycle inhibition. Our MTT and LDH results demonstrated that TC-1 cell viability after oncolytic RSV-A2 treatment was MOI-dependently and altered significantly with increasing RSV-A2 virus multiplicity of infection (MOI). Other findings showed that the RSV-A2 potentially resulted in apoptosis and autophagy induction, caspase-3 activation, ROS generation, and cell cycle inhibition in the TC-1 cell line. Real-time PCR assay revealed that RSV-A2 infection significantly elevated the Bax and decreased the Bcl2 expression. The results indicated that oncolytic RSV-A2 has cytotoxic and inhibiting effects on HPV-associated cervical cancer cells. Our findings revealed that RSV-A2 is a promising treatment candidate for cervical cancer.
Sections du résumé
BACKGROUND
BACKGROUND
Cervical cancer represents one of the most prevalent cancers among women worldwide, particularly in low- and middle-income nations. Oncolytic viruses (OVs) can infect cancer cells selectively and lethally without harming normal cells. Respiratory syncytial virus (RSV) is an oncolytic virus for anticancer therapy because of its propensity to multiply within tumor cells. This research aimed to assess the in vitro antitumor activities and molecular basis processes of the oncolytic RSV-A2 on the TC-1 cancer cells as a model for HPV‑related cervical cancers.
METHODS
METHODS
Cellular proliferation (MTT) and lactate dehydrogenase (LDH) release assays were used to investigate the catalytic impacts of RSV-A2 by the ELISA method. Real-time PCR and flow cytometry assays were utilized to assess apoptosis, autophagy, intracellular concentrations of reactive oxygen species (ROS), and cell cycle inhibition.
RESULTS
RESULTS
Our MTT and LDH results demonstrated that TC-1 cell viability after oncolytic RSV-A2 treatment was MOI-dependently and altered significantly with increasing RSV-A2 virus multiplicity of infection (MOI). Other findings showed that the RSV-A2 potentially resulted in apoptosis and autophagy induction, caspase-3 activation, ROS generation, and cell cycle inhibition in the TC-1 cell line. Real-time PCR assay revealed that RSV-A2 infection significantly elevated the Bax and decreased the Bcl2 expression.
CONCLUSIONS
CONCLUSIONS
The results indicated that oncolytic RSV-A2 has cytotoxic and inhibiting effects on HPV-associated cervical cancer cells. Our findings revealed that RSV-A2 is a promising treatment candidate for cervical cancer.
Identifiants
pubmed: 37641004
doi: 10.1186/s12885-023-11326-y
pii: 10.1186/s12885-023-11326-y
pmc: PMC10464077
doi:
Substances chimiques
Reactive Oxygen Species
0
Tumor Necrosis Factor-alpha
0
bcl-2-Associated X Protein
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
803Subventions
Organisme : Tehran University of Medical Sciences and Health Services
ID : 99-1-99-42374
Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
WHO, Cervical cancer:, WHO. 2022. Available from: https://www.who.int/news-room/fact-sheets/detail/cervical-cancer .
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209–49.
doi: 10.3322/caac.21660
Lei J, Ploner A, Elfström KM, Wang J, Roth A, Fang F, et al. HPV Vaccination and the risk of Invasive Cervical Cancer. N Engl J Med. 2020;383(14):1340–8.
doi: 10.1056/NEJMoa1917338
pubmed: 32997908
Stelzle D, Tanaka LF, Lee KK, Ibrahim Khalil A, Baussano I, Shah ASV, et al. Estimates of the global burden of cervical cancer associated with HIV. The Lancet Global Health. 2021;9(2):e161–e9.
doi: 10.1016/S2214-109X(20)30459-9
pubmed: 33212031
Keshavarz M, Nejad ASM, Esghaei M, Bokharaei-Salim F, Dianat-Moghadam H, Keyvani H, et al. Oncolytic Newcastle disease virus reduces growth of cervical cancer cell by inducing apoptosis. Saudi J Biol Sci. 2020;27(1):47–52.
doi: 10.1016/j.sjbs.2019.04.015
pubmed: 31889816
Han X, Wang S, Zhou W, Li Y, Lei WEN, Lv W. Synergistic combination of histone deacetylase inhibitor suberoylanilide hydroxamic acid and oncolytic adenovirus ZD55-TRAIL as a therapy against cervical cancer. Mol Med Rep. 2015;12(1):435–41.
doi: 10.3892/mmr.2015.3355
pubmed: 25684632
X Wanga HM, Leea J, Xiea C. Therapeutic implementation of oncolytic viruses for Cancer Immunotherapy: Review of Challenges and current clinical trials. J Biomedical Sci Res. 2022;4(2):1–13.
doi: 10.36266/JBSR/164
Keshavarz M, Ebrahimzadeh MS, Miri SM, Dianat-Moghadam H, Ghorbanhosseini SS, Mohebbi SR et al. Oncolytic Newcastle disease virus delivered by mesenchymal stem cells-engineered system enhances the therapeutic effects altering tumor microenvironment. Virol J. 2020;17(1).
Malhotra J, Kim ES. Oncolytic viruses and Cancer Immunotherapy. Curr Oncol Rep. 2022;25(1):19–28.
doi: 10.1007/s11912-022-01341-w
pubmed: 36441447
Lawler SE, Speranza M-C, Cho C-F, Chiocca EA. Oncolytic viruses in Cancer Treatment. JAMA Oncol. 2017;3(6):841.
doi: 10.1001/jamaoncol.2016.2064
pubmed: 27441411
Burton C, Bartee E. Syncytia formation in Oncolytic Virotherapy. Mol Therapy - Oncolytics. 2019;15:131–9.
doi: 10.1016/j.omto.2019.09.006
Li X, Sun X, Wang B, Li Y, Tong J. Oncolytic virus-based hepatocellular carcinoma treatment: current status, intravenous delivery strategies, and emerging combination therapeutic solutions. Asian J Pharm Sci. 2023;18(1):100771.
doi: 10.1016/j.ajps.2022.100771
pubmed: 36896445
Dong H, Li M, Yang C, Wei W, He X, Cheng G et al. Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages. Cancer Cell Int. 2023;23(1).
Mozaffari Nejad AS, Fotouhi F, Mehrbod P, Keshavarz M, Alikhani MY, Ghaemi A. Oncolytic effects of Hitchner B1 strain of newcastle disease virus against cervical cancer cell proliferation is mediated by the increased expression of cytochrome C, autophagy and apoptotic pathways. Microb Pathog. 2020;147:104438.
doi: 10.1016/j.micpath.2020.104438
pubmed: 32777353
Chang J. Current progress on development of respiratory syncytial virus vaccine. BMB Rep. 2011;44(4):232–7.
doi: 10.5483/BMBRep.2011.44.4.232
pubmed: 21524347
Mejias A, Rodríguez-Fernández R, Oliva S, Peeples ME, Ramilo O. The journey to a respiratory syncytial virus vaccine. Ann Allergy Asthma Immunol. 2020;125(1):36–46.
doi: 10.1016/j.anai.2020.03.017
pubmed: 32217187
pmcid: 7311299
Drysdale SB, Barr RS, Rollier CS, Green CA, Pollard AJ, Sande CJ. Priorities for developing respiratory syncytial virus vaccines in different target populations. Volume 12. Science Translational Medicine |REVIEW; 2020.
Tregoning JS, Schwarze Jr. Respiratory viral infections in infants: causes, clinical symptoms, Virology, and Immunology. Clin Microbiol Rev. 2010;23(1):74–98.
doi: 10.1128/CMR.00032-09
pubmed: 20065326
pmcid: 2806659
Domachowske JB, Anderson EJ, Goldstein M. The future of respiratory Syncytial Virus Disease Prevention and Treatment. Infect Dis Therapy. 2021;10(S1):47–60.
doi: 10.1007/s40121-020-00383-6
Salimi V, Yaraki MT, Mahmoodi M, Shahabi S, Gharagozlou MJ, Shokri F, et al. The Oncolytic Effect of Respiratory Syncytial Virus (RSV) in human skin Cancer cell line, A431. Iran Red Crescent Med J. 2013;15(1):62–7.
doi: 10.5812/ircmj.4722
pubmed: 23487261
pmcid: 3589781
al. Ze. Breast Cancer Therapy Using an Engineered Respiratory Syncytial Virus. United States Patent. 2013.
Choi SH, Park BK, Lee K-W, Chang J, Lee Y, Kwon H-J. Effect of respiratory syncytial virus on the growth of hepatocellular carcinoma cell-lines. BMB Rep. 2015;48(10):565–70.
doi: 10.5483/BMBRep.2015.48.10.268
pubmed: 25739391
pmcid: 4911183
Echchgadda I, Kota S, DeLa Cruz I, Sabbah A, Chang T, Harnack R, et al. Anticancer oncolytic activity of respiratory syncytial virus. Cancer Gene Ther. 2009;16(12):923–35.
doi: 10.1038/cgt.2009.34
pubmed: 19444304
pmcid: 2813688
Echchgadda I, Chang T-H, Sabbah A, Bakri I, Ikeno Y, Hubbard GB, et al. Oncolytic targeting of androgen-sensitive prostate tumor by the respiratory syncytial virus (RSV): consequences of deficient interferondependent antiviral defense. BMC Cancer. 2011;11:43.
doi: 10.1186/1471-2407-11-43
pubmed: 21276246
pmcid: 3038980
Kagabu M, Yoshino N, Saito T, Miura Y, Takeshita R, Murakami K, et al. The efficacy of a third-generation oncolytic herpes simplex viral therapy for an HPV-related uterine cervical cancer model. Int J Clin Oncol. 2020;26(3):591–7.
doi: 10.1007/s10147-020-01823-6
pubmed: 33146805
Leddon JL, Chen C-Y, Currier MA, Wang P-Y, Jung FA, Denton NL, et al. Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity. Mol Therapy - Oncolytics. 2014;1:14010.
doi: 10.1038/mto.2014.10
Wang Y, Li Y, Dong S et al. Jing Jin1, Dong5 Y, Liu3 F,. Stability and anti-tumor effect of oncolytic herpes simplex virus type 2. Oncotarget,. 2018;9(37):24672-83.
Hassan SAH, Allawe AB, Al-Shammari AM. In Vitro oncolytic activity of non-virulent Newcastle Disease Virus LaSota strain against mouse mammary adenocarcinoma. Iraqi J Sci. 2020;61(2):285–94.
doi: 10.24996/ijs.2020.61.2.5
Russell L, Peng K-W. The emerging role of oncolytic virus therapy against cancer. Chin Clin Oncol. 2018;7(2):16.
doi: 10.21037/cco.2018.04.04
pubmed: 29764161
pmcid: 6557159
Jung S, Jeong H, Yu S-W. Autophagy as a decisive process for cell death. Exp Mol Med. 2020;52(6):921–30.
doi: 10.1038/s12276-020-0455-4
pubmed: 32591647
pmcid: 7338414
Sun S-Y, Yue P, Zhou J-Y, Wang Y, Choi Kim H-R, Lotan R, et al. Overexpression of Bcl2 blocks TNF-Related apoptosis-inducing ligand (TRAIL)-Induced apoptosis in Human Lung Cancer cells. Biochem Biophys Res Commun. 2001;280(3):788–97.
doi: 10.1006/bbrc.2000.4218
pubmed: 11162590
Kalyanasundram J, Hamid A, Yusoff K, Chia SL. Newcastle disease virus strain AF2240 as an oncolytic virus: a review. Acta Trop. 2018;183:126–33.
doi: 10.1016/j.actatropica.2018.04.007
pubmed: 29626432
Mohammadian J, Shanehbandi, Samadi N, Sabzichi M, Molavi O. Dariush. Combined treatment with Stattic and Docetaxel alters the Bax/ Bcl-2 gene expression ratio in human prostate Cancer cells. Asian Pac J Cancer Prev. 2016;17(11):5031–5.
pubmed: 28032735
pmcid: 5454715
Pereira Soares NdC, Teodoro AJ, Oliveira FL, Takiya CM, Junior AP, Nasciutti LE, et al. Lycopene induce apoptosis in human prostate cells and alters the expression of bax and Bcl-2 genes. LWT - Food Science and Technology. 2014;59(2):1290–7.
doi: 10.1016/j.lwt.2014.04.028
Li S, Li Z, Chen S, Zhu Y, Li Y, Yin X, et al. Apoptotic and autophagic cell death induced in cervical cancer cells by a dual specific oncolytic adenovirus. Anticancer Drugs. 2022;34(3):361–72.
doi: 10.1097/CAD.0000000000001452
pubmed: 36730009
pmcid: 9891282
Doan P, Musa A, Candeias NR, Emmert-Streib F, Yli-Harja O, Kandhavelu M. Alkylaminophenol induces G1/S phase cell cycle arrest in Glioblastoma cells through p53 and cyclin-dependent kinase signaling pathway. Front Pharmacol. 2019;10.
Beth Levine1 aDJK. Development by Self-Digestion: Molecular Mechanisms and Biological Functions of Autophagy. Dev Cell. 2004;6:463–77.
doi: 10.1016/S1534-5807(04)00099-1
Hui G, Yu LL, Quan ZMaZ. Inactivated Sendai Virus induces apoptosis mediated by reactive oxygen species in murine melanoma cells. Bio med Environ Sci. 2016;29(12):877–84.
Han Z, Li Q, Sun S, Zhao W, Shi L. Inactivated Sendai virus strain Tianjin induces apoptosis and autophagy through reactive oxygen species production in osteosarcoma MG-63 cells. J Cell Physiol. 2018;234(4):4179–90.
doi: 10.1002/jcp.27176
pubmed: 30146726
Salehi F, Behboudi H, Kavoosi G, Ardestani SK. Chitosan promotes ROS-mediated apoptosis and S phase cell cycle arrest in triple-negative breast cancer cells: evidence for intercalative interaction with genomic DNA. RSC Adv. 2017;7(68):43141–50.
doi: 10.1039/C7RA06793C
Glick D, Barth S, Macleod KF. Autophagy: cellular and molecular mechanisms. J Pathol. 2010;221(1):3–12.
doi: 10.1002/path.2697
pubmed: 20225336
pmcid: 2990190
Jin S. p53, autophagy and tumor suppression. Autophagy. 2014;1(3):171–3.
doi: 10.4161/auto.1.3.2051
Yao G, Chen H, Chen L, Ge M, Yang J, Liu W, et al. Autophagy promotes apoptosis induction through repressed nitric oxide generation in the treatment of human breast cancer MCF-7 cells with L-A03, a dihydroartemisinin derivative. Med Chem Res. 2017;26(7):1427–36.
doi: 10.1007/s00044-017-1868-z
babaei A, Soleimanjahi H, Arefian E. Oncolytic reovirus shows potentially anticancer effect against CT26 cell lines 2019.
Igase M, Shibutani S, Kurogouchi Y, Fujiki N, Hwang CC, Coffey M, et al. Combination therapy with Reovirus and ATM inhibitor enhances cell death and virus replication in Canine Melanoma. Mol Therapy - Oncolytics. 2019;15:49–59.
doi: 10.1016/j.omto.2019.08.003